TCL Archive IL-2 Trials Proliferate; Biotherapeutics Sees NCI Proposal As Vindication Of Its Policies May 8, 1987
TCL Archive FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment. December 17, 2013